Protective effect of rebamipide against ammonia-induced gastric mucosal lesions. 1998

O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
Department of Biosignal Analysis, Osaka City University Medical School, Osaka, Japan.

We investigated the protective effect of rebamipide against ammonia-induced gastric mucosal lesions. Participation of prostaglandin E2 and nitric oxide in the action of rebamipide was also examined. Rebamipide was administered intraperitoneally (10-100 mg/kg) to male Wistar/ST rats (150-325 g) fasted for 24 hr. Thirty minutes later, 1% NH4OH (1 ml) solution was given intragastrically. One hour later, the length of the mucosal lesions was measured (lesion index), and prostaglandin E2 (PGE2) was determined by radioimmunoassay. A 1% NH4OH solution caused gastric mucosal lesions with hemorrhagic necrosis and submucosal edema. PGE2 synthesis was not affected by NH4OH but was significantly increased by rebamipide. Rebamipide decreased the severity of NH4OH-induced gastric mucosal lesions in a dose-dependent manner. Pretreatment with indomethacin (5 mg/kg, subcutaneously) did not affect the protective effect of rebamipide; however, pretreatment with N(omega)-nitro-L-arginine (L-NNA, 1-10 mg/kg, intravenously), an inhibitor of nitric oxide synthase, attenuated the protective effect of rebamipide in a dose-dependent manner. Simultaneous administration of L-arginine (100 mg/kg) and L-NNA completely restored the protective effect of rebamipide, whereas D-arginine was inactive. These results suggest that nitric oxide contributes significantly to the protective effect of rebamipide against ammonia-induced gastric mucosal lesions.

UI MeSH Term Description Entries
D008297 Male Males
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine
D000641 Ammonia A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. Note that the aqueous form of ammonia is referred to as AMMONIUM HYDROXIDE.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D013276 Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastric Ulcer,Gastric Ulcers,Stomach Ulcers,Ulcer, Gastric,Ulcer, Stomach,Ulcers, Gastric,Ulcers, Stomach
D015363 Quinolones A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID. Ketoquinoline,Ketoquinolines,Oxoquinoline,Oxoquinolines,Quinolinone,Quinolinones,Quinolone

Related Publications

O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
December 1989, Japanese journal of pharmacology,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
June 2010, Biochemical pharmacology,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
April 1994, Japanese journal of pharmacology,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
December 1999, World journal of gastroenterology,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
February 1998, Archives of pharmacal research,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
July 2013, Pharmaceutical biology,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
June 2017, Fundamental & clinical pharmacology,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
August 2003, Clinical and experimental pharmacology & physiology,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
February 2011, Digestive diseases and sciences,
O Takaishi, and T Arakawa, and K Yamasaki, and Y Fujiwara, and T Uchida, and K Tominaga, and T Watanabe, and K Higuchi, and T Fukuda, and K Kobayashi, and T Kuroki
May 2011, Canadian journal of physiology and pharmacology,
Copied contents to your clipboard!